Calprotectine in Spondyloarthritis

Study of the Interest of Serum Calprotectin Determination in the Diagnosis of Spondyloarthritis and to Diferenciate With Fibromyalgia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05555433

Acronym

Calprotectine

Enrollment

190

Registered

2022-09-26

Start date

2022-08-15

Completion date

2024-08-15

Last updated

2024-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spondylarthritis

Brief summary

To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology

Interventions

OTHERNO INTERVENTION

no intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients in the active line of the rheumatology department with one of the following criteria: active spondyloarthritis (BASDAI \>4), or spondyloarthritis in low activity (BASDAI\<4), or fibromyalgia without associated inflammatory rheumatism, or healthy subjects (without inflammatory rheumatism and without fibromyalgia. Patients who have not objected to the use of their samples

Exclusion criteria

Minor patient Subject not affiliated to the social security system Subject deprived of liberty Patient under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame	Description
calprotectine rate	5 months	blood test

Countries

France

Contacts

Primary ContactChristian ROUX, PUPH

roux.c2@chu-nice.fr33492035491

Backup ContactJeremy GENOVESE

genovese.j@chu-nice.fr33492035491

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026